NEW YORK (GenomeWeb News) – Sigma-Aldrich today said it is partnering with the Scripps Research Institute to develop and commercialize new reagents.

The deal, the company said, will "fund research and provide immediate day-of-publication access to [Scripps] researchers' discoveries for the synthesis and analysis of potential drugs," and, further, could "eliminate months from the translation of cutting-edge chemistry into widespread applications for drug discovery."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.